Investigational Drug Information for NSI-189
✉ Email this page to a colleague
What is the drug development status for NSI-189?
NSI-189 is an investigational drug.
There have been 5 clinical trials for NSI-189.
The most recent clinical trial was a Phase 1 trial, which was initiated on August 1st 2020.
The most common disease conditions in clinical trials are Depression, Depressive Disorder, and Disease. The leading clinical trial sponsors are Neuralstem Inc., Massachusetts General Hospital, and [disabled in preview].
Summary for NSI-189
| US Patents | 0 |
| International Patents | 30 |
| US Patent Applications | 19 |
| WIPO Patent Applications | 4 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 1 (2020-08-01) |
| Vendors | 52 |
Recent Clinical Trials for NSI-189
| Title | Sponsor | Phase |
|---|---|---|
| Buspirone and Melatonin for Depression Following Traumatic Brain Injury | Massachusetts General Hospital | Phase 4 |
| A Longitudinal Observational Cohort Study of NSI-189, With Out-Patients With Major Depressive Disorder | Neuralstem Inc. | |
| Study of NSI-189 for Major Depressive Disorder | Neuralstem Inc. | Phase 2 |
Clinical Trial Summary for NSI-189
Top disease conditions for NSI-189
Top clinical trial sponsors for NSI-189
US Patents for NSI-189
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for NSI-189
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| NSI-189 | Australia | AU2003293409 | 2023-08-08 | ⤷ Sign Up |
| NSI-189 | European Patent Office | EP1576134 | 2023-08-08 | ⤷ Sign Up |
| NSI-189 | World Intellectual Property Organization (WIPO) | WO2004053071 | 2022-12-09 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
